Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding

Inhibitors of cannabinoid receptors and glucose metabolism

(2009) André J Scheen et al.   CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE

Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine

(2008) Andreas Artmann et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Cannabidiol, extracted fromCannabis sativa, selectively inhibits inflammatory hypermotility in mice

(2008) R Capasso et al.   BRITISH JOURNAL OF PHARMACOLOGY

Rimonabant in rats with a metabolic syndrome: good news after the depression

(2008) V Di Marzo et al.   BRITISH JOURNAL OF PHARMACOLOGY

The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats

(2008) A Schäfer et al.   BRITISH JOURNAL OF PHARMACOLOGY

Guide to Receptors and Channels (GRAC), 3rd edition

(2008) S P H Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet

(2008) V Di Marzo et al.   BRITISH JOURNAL OF PHARMACOLOGY

Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between κ-opioid and cannabinoid CB1 receptors

(2008) R Capasso et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Acyclic CB1R Inverse Agonist Taranabant Mediates Weight Loss by Increasing Energy Expenditure and Decreasing Caloric Intake

(2008) Carol Addy et al.   Cell Metabolism

Endocannabinoid system in food intake and metabolic regulation

(2008) David Jesudason et al.   CURRENT OPINION IN LIPIDOLOGY

The Role of Adipocyte Insulin Resistance in the Pathogenesis of Obesity-Related Elevations in Endocannabinoids

(2008) T. M. D'Eon et al.   DIABETES

Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program

(2008) L. Van Gaal et al.   DIABETES CARE

The endocannabinoid system in obesity and type 2 diabetes

(2008) V. Di Marzo   DIABETOLOGIA

Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects

(2008) A A Izzo et al.   GUT

Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease

(2008) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice

(2008) Douglas Osei-Hyiaman et al.   JOURNAL OF CLINICAL INVESTIGATION

Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice

(2008) Gabriella Aviello et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Gastrointestinal Regulation of Food Intake: General Aspects and Focus on Anandamide and Oleoylethanolamide

(2008) R. Capasso et al.   JOURNAL OF NEUROENDOCRINOLOGY

Endocannabinoids, Adipose Tissue and Lipid Metabolism

(2008) C. Pagano et al.   JOURNAL OF NEUROENDOCRINOLOGY

Cannabinoid Type 1 Receptor: Another Arrow in the Adipocytes’ Bow

(2008) L. Bellocchio et al.   JOURNAL OF NEUROENDOCRINOLOGY

Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets

(2008) Isabel Matias et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Leptin controls adipose tissue lipogenesis via central, STAT3–independent mechanisms

(2008) Christoph Buettner et al.   NATURE MEDICINE

Endocannabinoid Dysregulation in the Pancreas and Adipose Tissue of Mice Fed With a High-fat Diet

(2008) Katarzyna M. Starowicz et al.   Obesity

The Orexigenic Effect of Ghrelin Is Mediated through Central Activation of the Endogenous Cannabinoid System

(2008) Blerina Kola et al.   PLoS One

Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins

(2008) M. A. Ruby et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

FAAH and anandamide: is 2-AG really the odd one out?

(2008) Vincenzo Di Marzo et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?

(2008) Vincenzo Di Marzo   Nature clinical practice. Cardiovascular medicine

Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes

(2007) I MATIAS   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Cannabinoid CB2receptors in the gastrointestinal tract: a regulatory system in states of inflammation

(2007) K L Wright et al.   BRITISH JOURNAL OF PHARMACOLOGY

Rimonabant: more than an anti-obesity drug?

(2007) B Costa   BRITISH JOURNAL OF PHARMACOLOGY

Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells

(2007) A M Malfitano et al.   BRITISH JOURNAL OF PHARMACOLOGY

Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats

(2007) T Croci et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions

(2007) V E Mendizábal et al.   BRITISH JOURNAL OF PHARMACOLOGY

Role and regulation of acylethanolamides in energy balance: focus on adipocytes and β-cells

(2007) I Matias et al.   BRITISH JOURNAL OF PHARMACOLOGY

Endocannabinoids and the gastrointestinal tract: what are the key questions?

(2007) G J Sanger   BRITISH JOURNAL OF PHARMACOLOGY